Carl Dieffenbach

Carl Dieffenbach


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2009 in JAMA
Verified
Journal Article
Closed access
PDF file
CDCarl Dieffenbach
Carl Dieffenbach
AFAnthony S. Fauci
Anthony S. Fauci
Opinion from JAMA — Universal Voluntary Testing and Treatment for Prevention of HIV Transmission

7 June 2011 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
CDCarl Dieffenbach
Carl Dieffenbach
AFAnthony S. Fauci
Anthony S. Fauci
As the third decade since AIDS was first recognized comes to an end, extraordinary advances have occurred in the understanding, treatment, and prevention of HIV infection and AIDS. As a result of these successes, it is now time to focus on future challenges. Paramount among these is reaching the goal of truly controlling and ultimately ending the HIV and AIDS pandemic. To that end, AIDS researchers and public health personnel worldwide are aggressively pursuing 3 key areas of scientific research. Given the availability of highly effective therapeutic regimens for HIV infection, the first challenge is efficiently identifying a maximum number of HIV-infected persons through voluntary HIV testing and initiating antiretroviral therapy (ART). Second, scientists are trying to develop a cure for HIV infection, which would alleviate the need for lifelong ART. Finally, preventing new cases of HIV infection, which currently number approximately 2.6 million per year globally, is critical to any attempt to end this pandemic. This article addresses each of these challenges and provides directions for the future.

8 June 2021 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
PLPaul R. De Lay
Paul R. De Lay
ABAdele Schwartz Benzaken
Adele Schwartz Benzaken
QKQuarraisha Abdool Karim
Quarraisha Abdool Karim
SASani Aliyu
Sani Aliyu
CACarolyn Amole
Carolyn Amole
SHShannon Hader
Shannon Hader
Paul De Lay and co-authors introduce a Collection on the design of targets for ending the AIDS epidemic.

1 January 2010 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
SKSusan C Kim
Susan C Kim
SBStephen Becker
Stephen Becker
CDCarl Dieffenbach
Carl Dieffenbach
BHBlair S Hanewall
Blair S Hanewall
CHCatherine Hankins
Catherine Hankins
MDMark R Dybul
Mark R Dybul
There are currently several ongoing or planned trials evaluating the efficacy of pre‐exposure prophylaxis (PrEP) as a preventative approach to reducing the transmission of HIV. PrEP may prove ineffective, demonstrate partial efficacy, or show high efficacy and have the potential to reduce HIV infection in a significant way. However, in addition to the trial results, it is important that issues related to delivery, implementation and further research are also discussed. As a part of the ongoing discussion, in June 2009, the Bill & Melinda Gates Foundation sponsored a Planning for PrEP conference with stakeholders to review expected trial results, outline responsible educational approaches, and develop potential delivery and implementation strategies. The conference reinforced the need for continued and sustained dialogue to identify where PrEP implementation may fit best within an integrated HIV prevention package. This paper identifies the key action points that emerged from the Planning for PrEP meeting.

1 March 2012 in Current Opinion in HIV and AIDS
Verified
Journal Article
Closed access
CDCarl Dieffenbach
Carl Dieffenbach
This review describes important aspects of the research agenda that have emerged as a result of the recent findings of the HIV transmission study in sero-discordant couples conducted by the National Institute of Allergy and Infectious Disease (NIAID)-supported HIV Prevention Trials Network (HPTN) and referred to as HPTN 052. The HPTN 052 study provided strong evidence that antiretroviral treatment (ART), given to HIV-infected partners with the purpose of achieving and maintaining full virologic suppression, could prevent linked HIV transmission in sero-discordant couples. These findings have implications in all future combination prevention strategies. The HPTN 052 study demonstrated that sustained virus suppression, below detectable levels, can prevent HIV transmission in sero-discordant couples. As a result of this study, we have now identified ART as a key component for all combination prevention strategies. Additionally, this study demonstrates that HIV testing is the single door of entry for individualized HIV treatment and prevention. The challenge now is to create a robust, seamless linkage and retention system so that the vision of HIV treatment as prevention can be realized. Such a system will maximize both the treatment and the prevention benefits of ART. The research agenda outlined here describes the need to extend this finding to areas of implementation science, such as the development of simpler, easier to use point-of-care assays for virus load, and improved, better tolerated, more durable combinations and formulations of antiretroviral drugs.

16 May 2020 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
CDCarl Dieffenbach
Carl Dieffenbach
AFAnthony S Fauci
Anthony S Fauci
Click on the article title to read more.